Cargando…

Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)

Chimeric antigen receptor (CAR) T cell therapy has emerged as a new and breakthrough cancer immunotherapy. Although CAR-T cell therapy has made significant progress clinically in patients with refractory or drug-resistant hematological malignancies, there are numerous challenges in its application t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Liqiang, Li, Yi, Muluh, Tobias Achu, Wang, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236127/
https://www.ncbi.nlm.nih.gov/pubmed/37274466
http://dx.doi.org/10.3892/ol.2023.13867
_version_ 1785052842778689536
author Zhong, Liqiang
Li, Yi
Muluh, Tobias Achu
Wang, Yongsheng
author_facet Zhong, Liqiang
Li, Yi
Muluh, Tobias Achu
Wang, Yongsheng
author_sort Zhong, Liqiang
collection PubMed
description Chimeric antigen receptor (CAR) T cell therapy has emerged as a new and breakthrough cancer immunotherapy. Although CAR-T cell therapy has made significant progress clinically in patients with refractory or drug-resistant hematological malignancies, there are numerous challenges in its application to solid tumor therapy, including antigen escape, severe toxic reactions, abnormal vascularization, tumor hypoxia, insufficient infiltration of CAR-T cells and immunosuppression. As a conventional mode of anti-tumor therapy, radiotherapy has shown promising effects in combination with CAR-T cell therapy by enhancing the specific immunity of endogenous target antigens, which promoted the infiltration and expansion of CAR-T cells and improved the hypoxic tumor microenvironment. This review focuses on the obstacles to the application of CAR-T technology in solid tumor therapy, the potential opportunities and challenges of combined radiotherapy and CAR-T cell therapy, and the review of recent literature to evaluate the best combination for the treatment of solid tumors.
format Online
Article
Text
id pubmed-10236127
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-102361272023-06-03 Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review) Zhong, Liqiang Li, Yi Muluh, Tobias Achu Wang, Yongsheng Oncol Lett Review Chimeric antigen receptor (CAR) T cell therapy has emerged as a new and breakthrough cancer immunotherapy. Although CAR-T cell therapy has made significant progress clinically in patients with refractory or drug-resistant hematological malignancies, there are numerous challenges in its application to solid tumor therapy, including antigen escape, severe toxic reactions, abnormal vascularization, tumor hypoxia, insufficient infiltration of CAR-T cells and immunosuppression. As a conventional mode of anti-tumor therapy, radiotherapy has shown promising effects in combination with CAR-T cell therapy by enhancing the specific immunity of endogenous target antigens, which promoted the infiltration and expansion of CAR-T cells and improved the hypoxic tumor microenvironment. This review focuses on the obstacles to the application of CAR-T technology in solid tumor therapy, the potential opportunities and challenges of combined radiotherapy and CAR-T cell therapy, and the review of recent literature to evaluate the best combination for the treatment of solid tumors. D.A. Spandidos 2023-05-16 /pmc/articles/PMC10236127/ /pubmed/37274466 http://dx.doi.org/10.3892/ol.2023.13867 Text en Copyright: © Zhong et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Zhong, Liqiang
Li, Yi
Muluh, Tobias Achu
Wang, Yongsheng
Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title_full Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title_fullStr Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title_full_unstemmed Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title_short Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
title_sort combination of car‑t cell therapy and radiotherapy: opportunities and challenges in solid tumors (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236127/
https://www.ncbi.nlm.nih.gov/pubmed/37274466
http://dx.doi.org/10.3892/ol.2023.13867
work_keys_str_mv AT zhongliqiang combinationofcartcelltherapyandradiotherapyopportunitiesandchallengesinsolidtumorsreview
AT liyi combinationofcartcelltherapyandradiotherapyopportunitiesandchallengesinsolidtumorsreview
AT muluhtobiasachu combinationofcartcelltherapyandradiotherapyopportunitiesandchallengesinsolidtumorsreview
AT wangyongsheng combinationofcartcelltherapyandradiotherapyopportunitiesandchallengesinsolidtumorsreview